UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 382

Sortiert nach

A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function

Diabetes, obesity & metabolism, 2013-06, Vol.15 (6), p.546-557

2013

Volltextzugriff (PDF)

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Diabetes, obesity & metabolism, 2014-04, Vol.16 (4), p.366-375

2014

Volltextzugriff (PDF)

A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia

Diabetic medicine, 2016-04, Vol.33 (4), p.478-487

2016

Volltextzugriff (PDF)

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials

Diabetes, obesity & metabolism, 2013-06, Vol.15 (6), p.564-571

2013

Volltextzugriff (PDF)

Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials

Diabetic medicine, 2013-02, Vol.30 (2), p.226-232

2013

Volltextzugriff (PDF)

Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study (EU‐TREAT)

Diabetic medicine, 2019-07, Vol.36 (7), p.868-877

2019

Volltextzugriff (PDF)

Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK

Journal of medical economics, 2015-01, Vol.18 (1), p.56-68

2015

Volltextzugriff (PDF)

Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management

Clinical obesity, 2016-08, Vol.6 (4), p.233-242

2016

Volltextzugriff (PDF)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes

Diabetes, obesity & metabolism, 2014-09, Vol.16 (9), p.869-872

2014

Volltextzugriff (PDF)

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

Economic burden of atherosclerotic cardiovascular disease: costs related to healthcare and loss of productivity; a matched case-control study in more than 450,000 Swedish individuals

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

Direct and indirect costs, early retirement, cardiovascular events and mortality in more than 50,000 adults with chronic heart failure in Sweden: a matched case-control study

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

PDB69 the Impact of Nocturnal Hypoglycemic Events on Functioning, Well-Being and Diabetes Management

Value in health, 2012-06, Vol.15 (4), p.A183-A183

2012

Volltextzugriff (PDF)

Benchmarks for interpretation of score differences on the SF-36 health survey

Value in health, 2013-05, Vol.16 (3), p.A35-A35

2013

Volltextzugriff (PDF)

PDB59 Nocturnal Hypoglycemic Events: Impacts on Patients Functioing, Well-Being and Diabetes Management

Value in health, 2011, Vol.14 (7), p.A482-A482

2011

Volltextzugriff (PDF)

Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review

Advances in radiation oncology, 2019-07, Vol.4 (3), p.520-531

2019

Volltextzugriff (PDF)

Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

PCR89 Impact of Dosing and Administration on HRQoL Among People With Hemophilia: A Time Trade-Off Study Including 2.250 Respondents in the UK, Canada and the US

Value in health, 2024-06, Vol.27 (6), p.S312-S312

2024

Volltextzugriff (PDF)

Reduced rates of overall hypoglycaemia in patients with Type 1 diabetes after switching to insulin degludec: A European, multinational, multicentre, prospective, observational study (ReFLeCT)

Diabetic medicine, 2019, Vol.36 (Suppl. 1), p.60

2019

Volltextzugriff (PDF)

PDB65 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

PDB64 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Value in health, 2013-11, Vol.16 (7), p.A442-A442

2013

Volltextzugriff (PDF)

PRM126 - Benchmarks for interpretation of score differences on the SF-36 health survey

Value in health, 2013-05, Vol.16 (3), p.A35-A35

2013

Volltextzugriff (PDF)

PO121 RATE RATIOS FOR NOCTURNAL CONFIRMED HYPOGLYCAEMIA WITH INSULIN DEGLUDEC VS. INSULIN GLARGINE USING DIFFERENT DEFINITIONS

Diabetes research and clinical practice, 2014-11, Vol.106, p.S109-S109

2014

Volltextzugriff (PDF)

PDB27 - Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Value in health, 2017-10, Vol.20 (9), p.A478-A479

2017

Volltextzugriff (PDF)

1 – 25 von 382

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(358)
Mit Volltextzugriff
(359)

Publikationsform

Sprache

Englisch
(382)
Japanisch
(48)

Erscheinungsjahr

n.n

Thema

Science & Technology
(196)
Life Sciences & Biomedicine
(151)
Humans
(132)
Oncology
(111)
Male
(105)
Female
(97)
Child
(79)
Hematology, Oncology And Palliative Medicine
(72)
Adolescent
(69)
Adult
(68)
Radiology
(68)
Child, Preschool
(64)
Biological And Medical Sciences
(49)
Radiology, Nuclear Medicine & Medical Imaging
(49)
Infant
(48)
Medical Sciences
(47)
Retrospective Studies
(43)
Physical Sciences
(40)
Materials Science
(39)
Middle Aged
(39)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia

A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials

Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials

Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non‐interventional study (EU‐TREAT)

Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK

Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

Economic burden of atherosclerotic cardiovascular disease: costs related to healthcare and loss of productivity; a matched case-control study in more than 450,000 Swedish individuals

Direct and indirect costs, early retirement, cardiovascular events and mortality in more than 50,000 adults with chronic heart failure in Sweden: a matched case-control study

PDB69 the Impact of Nocturnal Hypoglycemic Events on Functioning, Well-Being and Diabetes Management

Benchmarks for interpretation of score differences on the SF-36 health survey

PDB59 Nocturnal Hypoglycemic Events: Impacts on Patients Functioing, Well-Being and Diabetes Management

Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review

Estimating cardiovascular disease-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6

PCR89 Impact of Dosing and Administration on HRQoL Among People With Hemophilia: A Time Trade-Off Study Including 2.250 Respondents in the UK, Canada and the US

Reduced rates of overall hypoglycaemia in patients with Type 1 diabetes after switching to insulin degludec: A European, multinational, multicentre, prospective, observational study (ReFLeCT)

PDB65 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine for Patients with Type 2 Diabetes Mellitus Initiating Insulin Therapy in the United Kingdom

PDB64 - Cost-Effectiveness of Insulin Degludec Compared with Insulin Glargine in a Basal-Bolus Regimen in Patients with Type 1 Diabetes Mellitus in the United Kingdom

PRM126 - Benchmarks for interpretation of score differences on the SF-36 health survey

PO121 RATE RATIOS FOR NOCTURNAL CONFIRMED HYPOGLYCAEMIA WITH INSULIN DEGLUDEC VS. INSULIN GLARGINE USING DIFFERENT DEFINITIONS

PDB27 - Cost-Effectiveness of Switching To Insulin Degludec (IDEG) In Real-World Clinical Practice In Italy

Suchergebnisse filtern